Lipid Disorders
News
PCSK9 inhibitors flunk cost-effectiveness test
Key clinical point: PSCK9 inhibitors are not cost-effective for patients with heterozygous familial hypercholesterolemia or atherosclerotic...
News
Lipid screening in young adults still unsettled
News
Rises in LDL and HDL cholesterol, triglycerides tied to lower diabetes risk
Key clinical point: Elevated LDL cholesterol and triglyceride levels increase the risk of coronary artery disease but are linked with a lower risk...
News
Two incretin-based drugs linked to increased bile duct disease but not pancreatitis
Glucagon-like peptide 1 agonists do not appear to increase the risk of acute pancreatitis in individuals with diabetes but are associated with an...
News
Links found between NAFLD, type 2 diabetes, and NASH in children
Key clinical point: Nearly one in three children with nonalcoholic fatty liver disease have abnormal glucose metabolism, and this combination also...
News
ED visits rise with age in children, young adults with diabetes
News
Study shows faster increase in obesity prevalence among cancer survivors
Key clinical point: Cancer survivors had a significantly faster increase in obesity prevalence compared with adults without a history of cancer....
News
Metabolic health declining among the obese, despite improvements in BP and lipids
Key clinical point: Blood glucose and diabetes are on the rise among America’s obese. Major finding: Twenty-two percent of obese Americans now...
News
‘Clarion call’ to screen for, treat aldosteronism
Key clinical point: The Endocrine Society’s updated Clinical Practice Guideline for managing primary aldosteronism is “a clarion call” for...
Commentary
What difference would an empagliflozin CVD indication make?
Conference Coverage
FDA panel narrowly endorses empagliflozin’s cardiovascular mortality benefit
In a 12-11 vote, a Food and Drug Administration advisory panel narrowly came down in favor of the agency adding a new labeling entry to the...